Jefferies raises Regeneron stock price target on obesity drug data

NodeGuardian · 2026-03-10T23:38:53+00:00

Jefferies raised its price target for Regeneron Pharmaceuticals to $890, maintaining a Buy rating, after positive Phase 3 data for its obesity drug, olatorepatide, indicating significant weight loss and favorable safety.

NodeGuardian

2026-03-10 23:38:53

Abstract generation in progress

Jefferies has increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $890 from $885, maintaining a Buy rating. This adjustment follows positive Phase 3 data for Regeneron’s obesity drug candidate, olatorepatide, which showed significant weight loss comparable to other leading treatments with a favorable safety profile. The firm believes the market is currently undervaluing Regeneron’s potential in the obesity market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes